IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology for tumor destruction, announced the expiration and results of its rights offering, which was approximately two times over-subscribed, bringing in gross proceeds of $10.0 million. The subscription period ended on July 28, 2025. The rights offering allowed holders of record as of July 9, 2025, to purchase units at a subscription price of $1.00 per whole unit, facilitated through a registration statement on Form F-1 declared effective by the SEC. Maxim Group LLC acted as the dealer-manager for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.